Blueprint Medicines (BPMC) – Business Wire
-
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
-
IMV Appoints Kyle Kuvalanka to Board of Directors
-
Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Back to BPMC Stock Lookup
